6. パーキンソン病 Parkinson disease Clinical trials / Disease details
臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-101198 | 01/4/2010 | A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III) | A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III) | Parkinson's disease | Intervention name : Zonisamide Dosage And administration of the intervention : Oral Control intervention name : null | Dainippon Sumitomo Pharma Co., Ltd. | NULL | 20 | 74 | BOTH | 360 | Phase 3 | NULL | ||
| 2 | JPRN-JapicCTI-050099 | 12/09/2005 | Double blind, parallel-group clinical study of AD-810N (zonisamide) for Parkinson's disease | Double blind, parallel-group clinical study of AD-810N (zonisamide) for Parkinson's disease | Parkinson's disease | Intervention name : AD-810N (zonisamide) Dosage And administration of the intervention : oral | Dainippon Sumitomo Pharma Co., Ltd. | NULL | 20 | 79 | BOTH | NA | NULL | |||
| 3 | JPRN-JapicCTI-070377 | 28/03/2007 | Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's disease | Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's disease | Parkinson's disease | Intervention name : AD-810N (zonisamide) Dosage And administration of the intervention : oral | Dainippon Sumitomo Pharma Co., Ltd. | NULL | 20 | 74 | BOTH | Phase 3 | NULL |